DARZALEX FASPRO®DARZALEX®
This site is intended for US healthcare professionals.
DARZALEX FASPRO®DARZALEX®
Get in Touch
DARZALEX FASPRO®DARZALEX®
Expert VideosMOAAdditional RegimensNCCN GuidelinesPractice SupportPatient Support & Resources
Get in Touch
FAQs
Patient Site
MM Portfolio
For APPs & Nurses
For APPs
& Nurses
Check IconNOW
APPROVED

DARZALEX FASPRO® + VRd is approved in transplant-ineligible patients with newly diagnosed multiple myelomaNDMM1

DARZALEX FASPRO® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma1DARZALEX FASPRO® monotherapy is now approved in high-risk smoldering multiple myeloma1

Dosing
(DARZALEX FASPRO®
+ VRd)

Heading underline ImageHeading underline Image
Fixed-cycle dosing for patients in newly diagnosed, transplant-eligible multiple myeloma1

Dosing schedule with
DARZALEX FASPRO® + VRd regimen1*†

Dosing schedule with DARZALEX FASPRO® + VRd regimenDosing schedule with DARZALEX FASPRO® + VRd regimen

DARZALEX FASPRO® is the first and only subcutaneous anti-CD38 mAb injection delivered in ~3 to 5 minutes.1

ASCT=autologous stem cell transplant; CD38=cluster of differentiation 38; mAb=monoclonal antibody; VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).

*The first dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-4-week dosing schedule is given at Week 25. See the Dosage and Administration section of the full Prescribing Information for more details. When DARZALEX FASPRO® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.1

†Cycle=28 days.

Reference:

1. DARZALEX FASPRO® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.